Japan Skin Cancer Diagnostics Market Size, Share, and COVID-19 Impact Analysis, By Diagnostic Type (Biopsy, Dermatoscopy, Imaging, Blood Tests, and Others), By Technology (Molecular Diagnostics, Immunohistochemistry, Digital Pathology, and Others), By End User (Hospitals, Diagnostic Laboratories, Cancer Research Institutes, and Others), and Japan Skin Cancer Diagnostics Market Insights, Industry Trend, Forecasts to 2035

Japan Skin Cancer Diagnostics Market Insights Forecasts to 2035

• The Japan Skin Cancer Diagnostics Market Size Was Estimated at USD 462.6 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 4.21% from 2025 to 2035
• The Japan Skin Cancer Diagnostics Market Size is Expected to Reach USD 728.3 Million by 2035

According to a research report published by Spherical Insights & Consulting, The Japan Skin Cancer Diagnostics Market Size is anticipated to reach USD 728.3 million by 2035, growing at a CAGR of 4.21% from 2025 to 2035. The Japan skin cancer diagnostics market is expanding with rising incidence of cancer, advances in technology, and more awareness of the need for early detection. Government policies and robust healthcare infrastructure are also driving demand for reliable, affordable diagnostic equipment, supporting the market for continued expansion.

Market Overview

The Japan skin cancer diagnostics market refers to early detection and precise diagnosis of melanoma and non-melanoma skin cancers using tools like dermatoscopes, imaging systems, AI-powered algorithms, and biopsy techniques. These technologies are ubiquitous in hospitals, outpatient clinics, home care settings, and research facilities. Japan's advanced healthcare system and high healthcare expenditures underpin broad availability of diagnostic technologies, particularly among hospitals and outpatient settings. One of the growth prospects lies in remote diagnostics, which is facilitating more convenient access to screening. Growth for the market stems from increased cases of skin cancer due to UV exposure, as well as an aging population, and growing awareness of skin wellness. Government programs also contribute significantly by sponsoring early detection schemes and medical research, complementary to other Asia-Pacific initiatives to encourage national skin cancer screening and improved regional patient outcomes.

Report Coverage

This research report categorizes the market for the Japan skin cancer diagnostics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan skin cancer diagnostics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan skin cancer diagnostics market.

Driving Factors

The Japan market for skin cancer diagnostics is driven by an expanding aging population, heightened exposure to ultraviolet radiation, and rising incidence rates of skin cancers. Greater public education and government sponsored screening programs encourage early detection. Technological innovations like AI-driven diagnostic equipment, digital dermoscopy, and non-invasive imaging also improve adoption. Improved healthcare infrastructure and growing demand for personalized medicine also favor market growth. All factors combined facilitate the escalating need for precise and early diagnosis of skin cancer in Japan.

Restraining Factors

The Japan skin cancer diagnostic market is hindered by the high prices of sophisticated diagnostic equipment, restrictive reimbursement policies, and stringent regulatory clearances. The lack of trained dermatologists and unequal access to diagnostic technologies in rural regions also impede market growth.

Market Segmentation

The Japan skin cancer diagnostics market share is classified into diagnostic type, technology, and end user.

• The biopsy segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan skin cancer diagnostics market is segmented by diagnostic type into biopsy, dermatoscopy, imaging, blood tests, and others. Among these, the biopsy segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to they are accurate and reliable. Although invasive, innovations such as punch, shave, and excisional procedures have improved patient comfort and diagnostic accuracy. These advances offer fine information about cancerous tissues, further necessitating and proving the importance of biopsy interventions.

• The molecular diagnostics segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan skin cancer diagnostics market is segmented by technology into molecular diagnostics, immunohistochemistry, digital pathology, and others. Among these, the molecular diagnostics segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is attributed to the methods, such as PCR, NGS, and FISH provide accurate information on the molecular and genetic profile of skin cancer. They have revolutionized diagnostics through the identification of precise mutations and biomarkers, allowing early diagnosis, correct diagnosis, and the creation of personalized treatment plans based on the unique needs of a patient.

• The hospitals segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan skin cancer diagnostics market is segmented by end user into hospitals, diagnostic laboratories, cancer research institutes, and others. Among these, the hospitals segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.  This is owing to their extensive services and availability of cutting-edge diagnostic technology. Being major diagnostic and treatment facilities, they provide various kinds of tests and have specialized dermatology and oncology units, ensuring constant demand and consolidating diagnostic services in one facility.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan skin cancer diagnostics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Illumina
• Qiagen
• Terumo
• Kyowa Kirin
• Nikon Corporation
• GE Healthcare Technologies Inc.
• Fujirebio
• Michelson Diagnostics
• Thermo Fisher Scientific
• Novartis AG
• Roche
• Horiba
• Others

Recent Developments:

• In October 2022, Roche launched the Anti-PRAME (EPR20330) Rabbit Monoclonal Primary Antibody to detect PRAME protein in tissue samples. Widely expressed in melanomas, this antibody helps differentiate between benign and malignant lesions, aiding clinicians in making more accurate melanoma diagnostic decisions.

• In June 2021, Amgen and Kyowa Kirin announced a partnership to jointly develop and commercialize KHK4083, a potential first-in-class anti-OX40 monoclonal antibody for atopic dermatitis and other autoimmune diseases. Positive Phase 2 results support its advancement into Phase 3 for moderate-to-severe atopic dermatitis treatment.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan skin cancer diagnostics market based on the below-mentioned segments:

Japan Skin Cancer Diagnostics Market, By Diagnostic Type

• Biopsy
• Dermatoscopy
• Imaging
• Blood Tests
• Others

Japan Skin Cancer Diagnostics Market, By Technology

• Molecular Diagnostics
• Immunohistochemistry
• Digital Pathology
• Others

Japan Skin Cancer Diagnostics Market, By End User

• Hospitals
• Diagnostic Laboratories
• Cancer Research Institutes
• Others